PI3K Inhibitor Drug Class Market - 2024-2033

February 2026 | 247 pages | ID: PCD1C13ACD2DEN
DataM Intelligence

Abstracts

The PI3K Inhibitor Drug Class Market was valued at US$ 1.45 Billion in 2024 and is anticipated to reach US$ 2.3 Billion by 2033, at a CAGR of 0.055 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the PI3K Inhibitor Drug Class Market.

This report delivers a comprehensive overview of the PI3K Inhibitor Drug Class Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding PI3K Inhibitor Drug Class Market. The PI3K Inhibitor Drug Class Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

PI3K Inhibitor Drug Class Market Scope:

By Product

• PI3K? selective inhibitors
• PI3K? selective inhibitors
• PI3K?/? selective inhibitors
• Pan-Class I PI3K inhibitors
• Dual PI3K/mTOR inhibitors
• Other dual-target PI3K inhibitors

By Therapy Strategy

• Monotherapy
• Combination Therapy

By Route of Administration

• Oral
• Parenteral

By Line of Therapy

• First-Line Therapy (1L)
• Second-line (2L)
• Third-line and later (3L+)
• Maintenance / Long-term control

By Therapeutic Indication

• Oncology
• Hematologic Malignancies
• Non-Oncology

By Biomarker Status

• PIK3CA-mutated
• PI3K pathway activation (signature-based)
• PIK3CD / PIK3R1 variants
• PTEN loss / AKT pathway altered (exploratory)
• Biomarker-unselected

By Patient Demographics

• Pediatric
• Adult
• Geriatric

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies / E-Pharmacies
• Others

Key Players

• Novartis AG
• Gilead Sciences, Inc.
• Bayer AG
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• AbbVie Inc.
• Sanofi
• Merck & Co., Inc
• TG Therapeutics, Inc.
• Verastem, Inc.

Major Highlights

This report delivers a comprehensive overview of the PI3K Inhibitor Drug Class Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding PI3K Inhibitor Drug Class Market. The PI3K Inhibitor Drug Class Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period

2. EXECUTIVE SUMMARY

2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Precision-Oncology Pull from PIK3CA Mutation Testing
    3.1.1.2. Expanding Relapsed/Refractory Hematologic Cancer Pool
    3.1.1.3. Companion Diagnostic–Driven Prescribing Momentum
  3.1.2. Restraints
    3.1.2.1. Immune-Mediated Toxicity and Safety Black-Box Concerns
    3.1.2.2. Regulatory Tightening on Benefit–Risk Profiles
  3.1.3. Opportunity
    3.1.3.1. Next-Generation Isoform-Selective PI3K Innovation
    3.1.3.2. Combination Regimen Expansion Beyond Oncology
  3.1.4. Trends
    3.1.4.1. Shift from Pan-PI3K to Isoform-Specific Inhibitors
    3.1.4.2. Rising Withdrawals Reshaping Competitive Landscape
  3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter’s Five Force Analysis – Global PI3K Inhibitor Drug Class
4.2. Geopolitical & Supply Chain Exposure
  4.2.1. API Sourcing Concentration for PI3K Inhibitors
  4.2.2. Trade Policies, Export Controls, and Oncology Drug Supply Risks
4.3. Social & Patient-Centric Factors
  4.3.1. Physician Prescribing Behavior in Precision Oncology
  4.3.2. Brand Preference vs Therapeutic Switching Across PI3K Inhibitors
  4.3.3. Patient Switching Resistance Due to Toxicity Management and Monitoring Needs
  4.3.4. Awareness Gaps in Biomarker-Driven PI3K Therapy Selection
4.4. Economic Factors
  4.4.1. Reimbursement-Led Adoption in Public and Private Oncology Programs
  4.4.2. Inflationary Pressure on APIs, Complex Synthesis, and Oncology Manufacturing Inputs
  4.4.3. Currency Volatility Impacting Export-Oriented Targeted Oncology Drug Producers
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Prescription Oncology Ecosystem Participants
  4.10.1. Branded PI3K Inhibitor Innovators
  4.10.2. Emerging Generic and Next-Generation PI3K Developers
  4.10.3. API and High-Potency Intermediate Suppliers
  4.10.4. Contract Manufacturing and Oncology-Focused CDMOs
  4.10.5. Specialty Distributors, GPOs, and Oncology Procurement Bodies
4.11. Buyer Decision Criteria & Adoption Drivers
  4.11.1. Safety Profile Differentiation and Toxicity Management Support
  4.11.2. Regulatory Track Record and Post-Approval Compliance History
  4.11.3. Pricing Predictability Under Value-Based Oncology Frameworks
  4.11.4. Portfolio Synergies Across Targeted and Precision Oncology Therapies
4.12. DMI Opinion – Strategic Outlook for the Global PI3K Inhibitor Drug Class Market

5. BY PRODUCT

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  5.1.2. Market Attractiveness Index, By Product
5.2. PI3K? selective inhibitors*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. PI3K? selective inhibitors
5.4. PI3K?/? selective inhibitors
5.5. Pan-Class I PI3K inhibitors
5.6. Dual PI3K/mTOR inhibitors
5.7. Other dual-target PI3K inhibitors

6. BY THERAPY STRATEGY

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Strategy
  6.1.2. Market Attractiveness Index, By Therapy Strategy
6.2. Monotherapy*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Combination Therapy
  6.3.1. PI3K inhibitor + Endocrine therapy
  6.3.2. PI3K inhibitor + CDK4/6 inhibitor
  6.3.3. PI3K inhibitor + Anti-HER2 therapy
  6.3.4. PI3K inhibitor + Chemotherapy
  6.3.5. PI3K inhibitor + Immunotherapy
  6.3.6. PI3K inhibitor + Targeted therapy (non-PI3K)
  6.3.7. PI3K inhibitor + Anti-CD20 / chemoimmunotherapy regimens
  6.3.8. Other combinations

7. BY ROUTE OF ADMINISTRATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
  7.3.1. Intravenous
  7.3.2. Intramuscular
  7.3.3. Subcutaneous
  7.3.4. Intradermal

8. BY LINE OF THERAPY

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy
  8.1.2. Market Attractiveness Index, By Line of Therapy
8.2. First-Line Therapy (1L)*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Second-line (2L)
8.4. Third-line and later (3L+)
8.5. Maintenance / Long-term control

9. BY THERAPEUTIC INDICATION

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Indication
  9.1.2. Market Attractiveness Index, By Therapeutic Indication
9.2. Oncology*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  9.2.3. Solid Tumors
  9.2.4. Breast Cancer (HR+/HER2-, PIK3CA-mutated)
  9.2.5. Endometrial Cancer
  9.2.6. Head & Neck Squamous Cell Carcinoma
  9.2.7. Colorectal Cancer
  9.2.8. Non-Small Cell Lung Cancer
  9.2.9. Other solid tumors (basket / biomarker-driven)
9.3. Hematologic Malignancies
  9.3.1. Follicular Lymphoma
  9.3.2. Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL)
  9.3.3. Marginal Zone Lymphoma
  9.3.4. Diffuse Large B-Cell Lymphoma
  9.3.5. Mantle Cell Lymphoma
  9.3.6. Other Non-Hodgkin Lymphomas
  9.3.7. Other hematologic malignancies
9.4. Non-Oncology
  9.4.1. PIK3CA-Related Overgrowth Spectrum (PROS)
  9.4.2. Activated PI3K? Syndrome (APDS)
  9.4.3. Primary Immunodeficiency / Immune Dysregulation Disorders
  9.4.4. Autoimmune Disorders
  9.4.5. Inflammatory Diseases
  9.4.6. Other non-oncology indications

10. BY BIOMARKER STATUS

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status
  10.1.2. Market Attractiveness Index, By Biomarker Status
10.2. PIK3CA-mutated*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. PI3K pathway activation (signature-based)
10.4. PIK3CD / PIK3R1 variants
10.5. PTEN loss / AKT pathway altered (exploratory)
10.6. Biomarker-unselected

11. DIAGNOSTIC APPROACH

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach
  11.1.2. Market Attractiveness Index, By Diagnostic Approach
11.2. Tissue-based testing
11.3. Liquid biopsy (ctDNA)
11.4. Clinical phenotype-based (rare disease)

12. BY PATIENT DEMOGRAPHICS

12.1. Introduction
  12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
  12.1.2. Market Attractiveness Index, By Patient Demographics
12.2. Pediatric*
  12.2.1. Introduction
  12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Adult
12.4. Geriatric

13. BY DISTRIBUTION CHANNEL

13.1. Introduction
  13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  13.1.2. Market Attractiveness Index, By Distribution Channel
13.2. Hospital Pharmacies*
  13.2.1. Introduction
  13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Retail Pharmacies
13.4. Online Pharmacies / E-Pharmacies
13.5. Others

14. BY REGION

14.1. Introduction
  14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  14.1.2. Market Attractiveness Index, By Region
14.2. North America
  14.2.1. Introduction
  14.2.2. Key Region-Specific Dynamics
  14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity
  14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy
  14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Indication
  14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status
  14.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach
  14.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
  14.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  14.2.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    14.2.12.1. US
    14.2.12.2. Canada
    14.2.12.3. Mexico
14.3. Europe
  14.3.1. Introduction
  14.3.2. Key Region-Specific Dynamics
  14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity
  14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy
  14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Indication
  14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status
  14.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach
  14.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
  14.3.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  14.3.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    14.3.12.1. Germany
    14.3.12.2. UK
    14.3.12.3. France
    14.3.12.4. Russia
    14.3.12.5. Italy
    14.3.12.6. Spain
    14.3.12.7. Norway
    14.3.12.8. Netherlands
    14.3.12.9. Sweden
    14.3.12.10. Denmark
    14.3.12.11. Belgium
    14.3.12.12. Switzerland
    14.3.12.13. Austria
    14.3.12.14. Poland
    14.3.12.15. Finland
    14.3.12.16. Rest of Europe
14.4. Latin America
  14.4.1. Introduction
  14.4.2. Key Region-Specific Dynamics
  14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity
  14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy
  14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Indication
  14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status
  14.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach
  14.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
  14.4.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  14.4.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    14.4.12.1. Brazil
    14.4.12.2. Argentina
    14.4.12.3. Rest of Latin America
14.5. Asia-Pacific
  14.5.1. Introduction
  14.5.2. Key Region-Specific Dynamics
  14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity
  14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy
  14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Indication
  14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status
  14.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach
  14.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
  14.5.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  14.5.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    14.5.12.1. China
    14.5.12.2. India
    14.5.12.3. Japan
    14.5.12.4. Australia
    14.5.12.5. South Korea
    14.5.12.6. New Zealand
    14.5.12.7. Indonesia
    14.5.12.8. Malaysia
    14.5.12.9. Philippines
    14.5.12.10. Singapore
    14.5.12.11. Thailand
    14.5.12.12. Vietnam
    14.5.12.13. Rest of Asia-Pacific
14.6. Middle East and Africa
  14.6.1. Introduction
  14.6.2. Key Region-Specific Dynamics
  14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity
  14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy
  14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Indication
  14.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status
  14.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach
  14.6.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
  14.6.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  14.6.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    14.6.12.1. UAE
    14.6.12.2. Saudi Arabia
    14.6.12.3. South Africa
    14.6.12.4. Israel
    14.6.12.5. Egypt
    14.6.12.6. Turkey
    14.6.12.7. Qatar
    14.6.12.8. Kuwait
    14.6.12.9. Oman
    14.6.12.10. Bahrain
    14.6.12.11. Rest of Middle East and Africa

15. COMPETITIVE LANDSCAPE ANALYSIS

15.1. Competitive Scenario
15.2. Market Positioning/Share Analysis
15.3. Mergers and Acquisitions Analysis
15.4. Partner Identification Analysis
15.5. Investment & Funding Landscape
15.6. Strategic Alliances & Innovation Pipelines

16. COMPANY PROFILES

16.1. Novartis AG*
  16.1.1. Company Overview
  16.1.2. Product Portfolio
  16.1.3. Revenue Analysis
  16.1.4. Pricing Analysis
  16.1.5. SWOT Analysis
  16.1.6. Recent Developments
    16.1.6.1. Major Deals
    16.1.6.2. M&A
    16.1.6.3. Collaboration
    16.1.6.4. Acquisition
    16.1.6.5. Joint Ventures
    16.1.6.6. Innovations
  16.1.7. Recent News
    16.1.7.1. Events
    16.1.7.2. Conferences
    16.1.7.3. Symposiums
    16.1.7.4. Webinars
16.2. Gilead Sciences, Inc.
16.3. Bayer AG
16.4. F. Hoffmann-La Roche Ltd
16.5. Pfizer Inc.
16.6. AbbVie Inc.
16.7. Sanofi
16.8. Merck & Co., Inc
16.9. TG Therapeutics, Inc.
16.10. Verastem, Inc. (LIST NOT EXHAUSTIVE)

17. GLOBAL PI3K INHIBITOR DRUG CLASS MARKET – RESEARCH METHODOLOGY

17.1. Research Data
  17.1.1. Secondary Data
  17.1.2. Primary Data
  17.1.3. CAGR Analysis
17.2. Market Size Estimation Methodology
  17.2.1. Bottom-Up Approach
  17.2.2. Top-Down Approach
17.3. Market Breakdown & Data Triangulation
17.4. Research Assumptions
17.5. Limitations

18. APPENDIX

18.1. About Us and Services